Wire flash
China Post Securities: AI Drug Discovery Boosts Outsourcing Demand, Overseas CXO Orders Recover
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
A research report from China Post Securities on the pharmaceutical and biomedical industry argues that AI-driven drug discovery is expected to increase the number of candidate molecules and wet-lab experiments, thereby boosting outsourcing demand and creating a long-term tailwind for Contract Research Organizations (CXOs). The report highlights that leading companies such as Charles River Laboratories (CRL), IQVIA (IQV), and Thermo Fisher Scientific (TMO) are strengthening their AI capabilities through acquisitions and partnerships, converting these into order advantages. The report notes that in the second quarter of 2026, overseas CXO demand recovered and orders improved, with 8 out of 14 tracked companies raising their full-year guidance. New contract signings for clinical and preclinical CROs improved, while CDMO demand remained strong but capacity ramp-up pressured profits. The report maintains an 'outperform' rating for the sector, while cautioning about risks related to financing, competition, and exchange rates.
Source report
Title: Preparing for Takeoff: How Leading CXO Companies Are Embracing AI (and Global CXO 2026 Interim Performance Review)
Date: October 9, 2026 Source: China Post Securities – Pharmaceutical & Biotech Industry Report
Key Takeaways
China Post Securities' pharmaceutical and biotech research report highlights that AI-driven drug discovery is expected to increase the number of candidate molecules and wet-lab projects, thereby boosting outsourcing demand and creating a long-term tailwind for the CXO sector.
AI Integration by Industry Leaders
Leading CXO companies—including Charles River Laboratories (CRL), IQVIA (IQV), and Thermo Fisher Scientific (TMO)—are strengthening their AI capabilities through acquisitions and partnerships, converting these investments into competitive advantages in order intake.
Global CXO Performance in 2026H1
- Demand recovery: Overseas CXO demand showed signs of recovery in Q2 2026, with order backlogs improving.
- Guidance upgrades: Among 14 tracked companies, 8 raised their full-year guidance.
- Segment performance:
- Clinical and preclinical CROs reported improved new contract signings.
- CDMO demand remained strong, though capacity ramp-up continued to pressure margins.
Rating and Risks
- Rating: Maintained Outperform for the sector.
- Key risks: Fluctuations in biotech financing, intensifying competition, and foreign exchange volatility.
Source
research_reportEastern